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CD81 T-cell responses to hepatitis C virus (HCV) are important in generating a suc-
cessful immune response and spontaneously clearing infection. Human leukocyte anti-
gen (HLA) class I presents viral peptides to CD81 T cells to permit detection of
infected cells, and tapasin is an important component of the peptide loading complex
for HLA class I. We sought to determine if tapasin polymorphisms affected the outcome
of HCV infection. Patients with resolved or chronic HCV infection were genotyped for
the known G/C coding polymorphism in exon 4 of the tapasin gene. In a European,
but not a US, Caucasian population, the tapasin G allele was significantly associated
with the outcome of HCV infection, being found in 82.5% of resolvers versus 71.3% of
persistently infected individuals (P5 0.02, odds ratio [OR]5 1.90 95% confidence
interval [CI]5 1.11-3.23). This was more marked at the HLA-B locus at which hetero-
zygosity of both tapasin and HLA-B was protective (P< 0.03). Individuals with an
HLA-B allele with an aspartate at residue 114 and the tapasin G allele were more likely
to spontaneously resolve HCV infection (P< 0.00003, OR5 3.2 95% CI5 1.6-6.6).
Additionally, individuals with chronic HCV and the combination of an HLA-B allele
with an aspartate at residue 114 and the tapasin G allele also had stronger CD81 T-cell
responses (P5 0.02, OR5 2.58, 95% CI-1.05-6.5). Conclusion: Tapasin alleles contrib-
ute to the outcome of HCV infection by synergizing with polymorphisms at HLA-B in
a population-specific manner. This polymorphism may be relevant for peptide vaccina-
tion strategies against HCV infection. (HEPATOLOGY 2013;58:881-889)
H
epatitis C virus (HCV) is a common chronic
viral infection with between 50% and 80%
of individuals exposed to HCV becoming
chronically infected. Understanding the immunological
determinants of resolution of HCV infection is impor-
tant in order to develop vaccines and also immunolog-
ically based therapeutics. A broad and multispecific
CD81 T-cell response may be important in resolving
HCV infection successfully. The strength of this
CD81 response is dependent on a number of factors.
These include antigen processing and presentation, an
appropriate cytokine microenvironment, and the
presence of CD41 T-cell help. In addition to these
cellular factors, host genetic factors may also play an
important role. Specific human leukocyte antigen
(HLA) class I alleles are associated with the outcome
of HCV infection, and certain HLA class I alleles,
including HLA-B*27 and B*57, are associated with a
strong CD81 response and hence viral clearance.1-8
The selection of HCV peptides for presentation is
determined by the allelic diversity of HLA and also the
supply of HCV peptides to the endoplasmic reticulum.
Additionally, peptide loading of HLA class I is complex.
It involves several proteins including tapasin, TAP,
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ERp57, and calreticulin that together form a peptide
loading complex (PLC) (Fig. 1).9 Overall, these proteins
act in a collaborative way to properly fold HLA class I
with b2-microglobulin and endogenous or virally
derived peptides. ERp57 and calreticulin promote fold-
ing and disulphide bond formation of HLA class I,
while tapasin acts as a “bridge” between the components
of the PLC.10 In doing so it is thought to promote the
binding of high-affinity peptides to HLA class I for pre-
sentation on the cell surface11,12 (Fig. 1). In the presence
or absence of tapasin the hierarchy of peptides presented
by HLA class I can be substantially different.13,14 How-
ever, only certain HLA class I alleles have been shown to
be tapasin-dependent in biochemical assays. These
include HLA-A*3001, HLA-B*2705, HLA-B*3501,
HLA-B*4402, HLA-B*5001, and HLA-B*5701.15-17
This dependence is governed by residues 114, 116, and
156 of the HLA class I molecule, in the floor of the pep-
tide binding groove.11,16,18,19 Thus, tapasin can have a
direct effect on peptide binding to HLA class I, and as
the tapasin gene lies at the centromeric end of the major
histocompatability complex (MHC), but is beyond a
recombination hotspot, it is not thought to be in tight
linkage with HLA class I.20,21 The tapasin gene has a
number of single nucleotide polymorphisms (SNPs).21-
24 However, of the exonic SNPs only one is nonsynony-
mous and both alleles are commonly found in the Cau-
casian population.24 This SNP is in exon 4 and codes
for a nonconservative arginine to threonine substitution
at position 260 of the tapasin protein. The aim of this
study was to determine whether polymorphisms in tapa-
sin and HLA class I may interact to determine the out-
come of HCV infection.
Patients and Methods
Patients
All patients provided written informed consent and
participated in the study in agreement with the rele-
vant local Ethics Committee’s approval and the Decla-
ration of Helsinki.
UK Cohort 1. These individuals were from the pre-
viously described UK cohort of HCV-exposed individu-
als,25 with the addition of 71 chronically infected
individuals. Patients were recruited from hepatology
clinics at King’s College Hospital, London; Adden-
brooke’s Hospital NHS Trust, Cambridge; and South-
ampton General Hospital, Southampton, UK. There
were 120 (37 female, 83 male, mean age 41.5 years)
individuals with resolved infection. All had a self-
reported Caucasian ethnicity and had at least two nega-
tive polymerase chain reaction (PCR) reactions (HCV
COBAS Amplicor; Roche Diagnostics, Pleasanton, CA)
at least 6 months apart. The chronic HCV population
consisted of 300 chronically infected individuals (81
female, 219 male, mean age 43.0 years). Two hundred
and eighty-six (95.3%) had a self-reported Caucasian
ethnicity.
UK Cohort 2. These consisted of a cohort of 79 (64
male) Caucasian individuals with an extensive history of
injection drug use, but repeated negative testing for
HCV antibody, as previously described.26 This group
has been termed HCV-exposed seronegative aviremic.
The median duration of injection drug use was 8.62
years (range, 0.3-24) with a median number of injec-
tions of 4,927 (range, 36-41,620). Their median age
was 28 years. As a control group 79 additional individu-
als with chronic HCV infection were recruited from the
outpatient hepatology clinic at Southampton General
Hospital. Fifty-seven were male and 75 (94.9%) were of
Caucasian origin. The mean age at diagnosis was 48.4.
German Cohort. Forty-two patients (17 female,
25 male, mean age 48.6 years) with chronic HCV
from the University Hospital Freiburg were included.
Thirteen had genotype 1a and 29 genotype 1b infec-
tion. All patients had a Caucasian self-reported ethnic-
ity. Sixteen of the patients were positive for HLA-
B*18, 17 for HLA-B*35, six for HLA-B*57, and six
for HLA-B*58 (three of the patients were positive for
two of these HLA alleles). Peripheral blood mononu-
clear cells (PBMCs) were isolated from patient blood
by gradient centrifugation, as described.27
US Cohort. These individuals were from the previ-
ously described USA cohort of HCV-exposed individu-
als limited to those of Caucasian ethnicity.8 Briefly,
patients were recruited from the infectious diseases or
hepatology clinics at Massachusetts General Hospital
with local Ethics Committee approval. There were 53
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(27 female, 26 male, mean age 39.2 years) individuals
with resolved infection. Each had at least two negative
PCR reactions (HCV COBAS Amplicor; Roche Diag-
nostics) at least 6 months apart, and 196 chronically
infected individuals (69 female, 127 male, mean age
41.4 years).
Genotyping
Tapasin genotyping was performed on genomic DNA
extracted using a QiaAmp DNA Blood mini kit (Qiagen,
Crawley, UK). A 51 basepair region of the tapasin gene
flanking the polymorphism was amplified using the pri-
mers 50-GACCTTCTGGCTGCCTAC-30 (G allele) and
50-GACCTTCTGGCTGCCTAG-30 (C allele) and 50-GC
CAGATAGGTGCCCTCCTG-30 (reverse). PCR reactions
were detected using the Quantitect SYBR Green PCR kit
(Qiagen) in standard 20 lL PCR reactions. Thermal cy-
cling conditions were: 95C for 10 minutes, followed by
40 cycles of 95C for 15 seconds, and 58C for 20 seconds.
HLA genotyping was performed by PCR-SSP as
described28 or at NCI Frederick (Dr. Mary Carrington) by
the PCR-SSOP (sequence-specific oligonucleotide probing)
typing protocol and PCR-SBT (sequence based typing) as
recommended by the 13th International Histocompatibility
Workshop (http://www.ihwg.org).
Generation of Peptide-Specific T-Cell Lines
Peptides (Table 1) were synthesized by Genaxxon
BioScience (Ulm, Germany) and have a purity of at
least 70%. Peptide-specific T-cell lines were generated
as described.29 4 3 106 PBMC were resuspended in
1 mL medium and stimulated with peptide at a final
concentration of 10 lg/mL and anti-CD28 (BD Phar-
Mingen) at a final concentration of 0.5 lg/mL. On
days 3 and 10, 1 mL culture medium and recombi-
nant IL-2 (Hoffmann-La Roche, Basel, Switzerland) at
a final concentration of 20 U/mL was added to each
well. On day 7, the cultures were restimulated with
the corresponding peptide (10 lg/mL) and 106 irradi-
ated autologous feeder cells. After 2 weeks, PBMC
were tested for peptide-specific interferon-gamma
Fig. 1. Schematic showing the role of tapasin in peptide loading. Tapasin along with the transporter associated with antigen processing (TAP),
ERp57, and calreticulin form the peptide loading complex (PLC), which loads viral peptides onto HLA class I. Tapasin binds to HLA class I and is
thought to assist in the dissociation of peptides that bind with low affinity. These dissociated peptides can be replaced by high-affinity peptides.
When a high-affinity peptide binds HLA class I the HLA class I and peptide are released from tapasin and the PLC and egress to the cell surface.
Table 1. CD81 T-Cell Epitopes Analyzed
HLA Allele Protein Position Epitope
B*18 NS5A 2143-2151 DEVSFRVGL(gt 1a)/
DEVTFQVGL(gt 1b)
NS3 1581-1589 DNFPYLVAY(gt 1b only)
B*35 E1 234-242 NASCRCWVAV(gt 1a)/
NSSCRCWVAL(gt 1b)
NS3 1359-1367 HPNIEEVAL
NS4A 1695-1702 IPDREVLY
NS5A 2163-2171 EPEPDVAVL
B*57/B*58 E2 521-529 RSGAPTYSW
E2 541-550 NTRPPLGNWF
E2 708-716 SIASWAIKW
NS3 1596-1604 RAQAPPPSW
NS4 1968-1972 CTTPCSGSW
NS5B 1801-1809 LTTSQTLLF
NS5B 2629-2637 KSKKTPMGF
NS5B 2912-2921 LGVPPLRAWR
HEPATOLOGY, Vol. 58, No. 3, 2013 ASHRAF ET AL. 883
(IFN-c) production by intracellular cytokine staining
after 5 hours of restimulation with the respective pep-
tide (10 lg/mL) as described.29 Peptides were matched
to the HLA-B alleles of the respective patients.
Statistical Analysis
This was performed using SPSS v. 17.0 and using the
Bonferroni correction where necessary. Specifically for
the residue analysis the correction factor was n5 34,
which is the number of different residues at the analyzed
positions (114, 116, and 156) at all three loci.
Results
The Tapasin G Allele Is Protective Against
Chronic HCV Infection. We typed 120 individuals
with resolved and 300 individuals with chronic HCV
infection for the G/C SNP in exon 4 of tapasin. Ninety-
nine (82.5%) out of 120 individuals with resolved infec-
tion versus 214 (71.3%) out of 300 individuals with
chronic infection had the G allele, which encodes for
the arginine variant (P5 0.019, odds ratio [OR]5 1.90
95% confidence interval [CI]5 1.11-3.23) (Table 2a).
Similar frequencies of individuals with the tapasin C al-
lele had resolved as compared to chronic HCV infection
(70.8% versus 74.3%, P> 0.1). Thus, the tapasin G al-
lele is associated with protection against chronic HCV
infection in this cohort.
Tapasin Advantage Is Related Mainly to HLA-B
Alleles. Tapasin helps to optimize the MHC class I
peptide repertoire and some MHC class I alleles are
more dependent on tapasin for optimization of their
peptide repertoire than others. We therefore explored
how this property was manifest in a more in-depth
immunogenetic analysis. We hypothesized that hetero-
zygosity of MHC class I and also of tapasin could be
predicted to increase the number of peptides presented
to CD81 T cells and hence augment the immune
response to HCV. We therefore determined the associa-
tion of heterozygosity for tapasin with the outcome of
infection. In this analysis heterozygosity at HLA class I
was defined as alleles with different HLA types as deter-
mined by four-digit typing, which correlates with differ-
ences at the single amino acid level. Sixty-four (53.3%)
of resolvers and 137 (45.7%) of chronically infected
individuals were heterozygous for tapasin (P> 0.1).
Thus, for both spontaneous resolvers and chronically
infected individuals the individual gene frequencies were
in Hardy-Weinberg equilibrium. However, when indi-
vidual HLA class I loci were considered there was a
trend for the combined association of heterozygosity of
tapasin with HLA-B heterozygosity with outcome
(P5 0.028, Pc5 0.084 (v
2 trend test)), but not for
tapasin and heterozygosity at the other loci (Fig. 2).
Although some HLA class I alleles are more tapasin-
dependent than others, we found only relatively weak
associations of outcome and specific HLA class I alleles
with the tapasin G and C alleles. These associations
include resolution of HCV and the tapasin G allele in
Table 2. Association of Tapasin Alleles With Outcome
in the Different Cohorts
a) UK: Spontaneous Resolving Cohort
Tapasin Allele Resolver (n5 120) Chronic (n5 300) P Value OR 95% CI
C 85 (70.8%) 223 (74.3%) 0.47 0.84 0.52-1.3
G 99 (82.5%) 214 (71.3%) 0.02 1.90 1.11-3.23
b) USA: Spontaneous Resolving Cohort
Tapasin Allele Resolver (n5 53) Chronic (n5 196) P Value
C 38 (71.7%) 145 (74.0%) >0.1
G 43 (81.1%) 160 (81.7%) >0.1
c) UK: Exposed Uninfected Cohort
Tapasin Allele Exposed Uninfected (n5 75) Chronic (n5 79) P Value
C 54 (72.0%) 60 (75.9%) >0.1
G 63 (84.0%) 60 (75.9%) >0.1
Fig. 2. Heterozygosity of tapasin and HLA-B are protective against chronic HCV infection. Analysis of the combination of tapasin heterozygosity
with HLA heterozygosity at HLA-A, HLA-B, and HLA-C. Heterozygosity was determined at the four-digit level. Numbers in each group are indicated
above the relevant bars. P Values were calculated using a chi-square test for trend and the Bonferroni correction applied (Pc).
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individuals who were positive for HLA-A*0101
(P5 0.008, OR5 3.17, 95% CI 1.4-7.5), B*0702
(P5 0.01, OR5 4.84, 95% CI 1.3-17.6), and
Cw*0701 (P5 0.04, OR5 2.69, 95% CI 1.07-6.77).
Conversely, the tapasin C allele was associated with
chronic infection in individuals who had the B*0801
allele (P5 0.008, OR5 0.23, 95% CI 0.08-0.66) and
the B*3501 allele (P5 0.01, OR5 0.16, 95% CI
0.04-0.65).
The Protective Effect of Tapasin G Alleles Is
Determined by Specific HLA Class I Residues. Bio-
chemical studies have indicated that specific HLA-class
I residues may be relevant for their interaction with
tapasin. In particular, residues 114, 116, and 156 of
the MHC class I heavy chain determine its interaction
with tapasin, with the effect of position 114 being
dominant over 116.14-16,30 We therefore investigated
whether these residues determined the association of
the tapasin G allele with the outcome of HCV infec-
tion. As the three class I loci have distinct sequences
we subdivided the analysis by locus, so that in each
analysis 2n alleles were considered (Table 3). One hun-
dred and twenty-seven out of 143 (89%) of HLA-B
alleles with aspartate at residue 114 (Asp114) were
associated with the tapasin G allele in individuals who
resolved infection, as compared to 234 out of 330
(71%) of HLA-B alleles from those with chronic infec-
tion (P< 0.00003 (Pc5 0.0009), OR5 3.26, 95%
CI5 1.84-5.77) (Table 3). Overall, 105 resolvers had
at least one HLA-B allele with Asp114, and 93 (89%)
of these had a tapasin G allele, as compared to 174 of
246 (71%) individuals with chronic infection
(P5 0.0002, OR5 3.50, 95% CI5 1.77-6.93). How-
ever, the presence of an HLA-B allele with Asp114 per
se was not significantly associated with resolution
(P> 0.1).
A similar, but weaker, association of the tapasin G
allele with Asp114 was seen at HLA-C, as this combi-
nation was found in 144 out of 177 alleles (81%) in
resolvers but only 286 out of 406 (70%) in chronically
infected individuals (P5 0.006 (Pc>0.05), OR5 1.83,
95% CI5 1.19-2.83) (Table 3). The only other posi-
tive association to remain after Bonferroni correction
(n5 34) was for serine at residue 116 of an HLA-C
allele. One hundred out of 120 HLA-C alleles with
Ser116 were associated with tapasin G (83%) in
resolvers versus 202 out of 304 (66%) in chronically
infected individuals (P5 0.0005 (Pc5 0.015),
OR5 2.53, 95% CI5 1.48-4.32). This association
was also shared with HLA-B alleles, in which Ser116
was found in 64 out of 72 (89%) of resolvers versus
93 out of 128 (73%) chronically infected individuals
Table 3. Association of the Tapasin (Tsn) G Allele With Specific
Amino Acid Residues in the HLA Class I Heavy Chain
a) HLA-A
Residue N
Resolve Chronic
P Value OR 95% CITsn G1 Tsn G2 Tsn G1 Tsn G2
114
Glu 11 1 1 7 2
His 317 86 16 153 62 0.012 2.18 1.18-4.01
Gln 99 16 5 57 21
Arg 399 91 20 203 85 0.022 1.91 1.1-3.29
116
Asp 498 107 25 260 106 0.028 1.75 1.07-2.85
His 11 1 1 7 2
Tyr 317 86 16 153 62 0.012 2.18 1.18-4.01
156
Leu 481 114 19 262 86 0.014 1.97 1.14-3.39
Gln 120 24 7 60 29
Arg 148 43 8 61 36 0.008 3.17 1.34-7.5
Try 77 13 8 37 19
b) HLA-B
Residue N
Resolve Chronic
P Value Pc Value OR 95% CITsn G1 Tsn G2 Tsn G1 Tsn G2
114
Asp 473 127 16 234 96 <0.00003 0.0009 3.26 1.84-5.77
His 32 9 4 18 1
Asn 317 62 20 160 75
116
Asp 185 40 8 102 35
Phe 65 15 5 27 18
Leu 66 9 4 40 13
Ser 200 64 8 93 35 0.007 3.01 1.3-6.91
Try 306 70 15 150 71 0.011 2.21 1.18-4.13
156
Asp 217 46 7 108 56 0.003 3.41 1.45-8.04
Leu 438 100 25 226 87
Arg 110 32 4 51 23 0.032 3.61 1.14-11.4
Try 57 20 4 27 6
c) HLA-C
Residue N
Resolve Chronic
P Value Pc Value OR 95% CITsn G1 Tsn G2 Tsn G1 Tsn G2
114
Asp 583 144 33 286 120 0.006 1.83 1.19-2.83
Asn 231 46 9 124 52
116
Phe 247 52 10 132 53
Leu 21 1 3 13 4
Ser 424 100 20 202 102 0.0005 0.015 2.53 1.48-4.32
Try 122 37 9 63 13
156
Asp 15 6 1 7 1
Leu 371 94 23 179 75
Gln 38 6 2 18 12
Arg 258 51 10 139 58 0.047 2.13 1.01-4.48
Try 132 33 6 67 26
Shown are the number of HLA alleles with each specific residue at positions
114, 116 and 156 in the tapasin G-positive and G-negative groups in individu-
als that resolved HCV infection or remained chronically infected. Only P values,
or Bonferroni corrected P values <0.05 are shown.
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(P5 0.007 (Pc>0.1), OR5 3.01, 95% CI5 1.3-6.9).
Of note is that neither Asp114 nor Ser116 are present
in any of the HLA-A alleles present in our population.
Conversely, Arg156 is present in alleles at all three loci
and this was associated with resolution in combination
with tapasin G at: HLA-A in 43 out of 51 (84%) ver-
sus 61 out of 97 (63%) (P5 0.008 (Pc > 0.1),
OR5 3.17, 95% CI5 1.3-7.5); HLA-B 32 out of 36
(89%) versus 51 out of 74 (69%) (P5 0.03 (Pc >
0.1), OR5 3.61, 95% CI5 1.1-11.4) and HLA-C 51
out of 61 (84%) versus 139 out of 197 (71%)
(P5 0.05 (Pc > 0.1), OR5 2.13, 95% CI5 1.0-4.5)
in resolvers versus chronically infected individuals,
respectively. Thus, we found a consistent trend for this
residue to be significantly associated with tapasin G
and the outcome of HCV infection.
In order to determine whether the effects we noted
were due to the association of specific HLA class I resi-
dues with a tapasin G allele or were independent, we
performed logistic regression analysis using the most
significantly associated residues at each locus (those
with P< 0.01) and tapasin G as the variables (Table
4a-c). In these three analyses tapasin G remained sig-
nificant throughout. However, for HLA-A alleles no
significant associations remained. For HLA-B alleles
Asp114 (P5 0.027) and Asp156 (P5 0.048) remained
significantly associated with resolution in combination
with the tapasin G allele, with a trend towards chron-
icity in the absence of tapasin G (Table 4b). However,
at HLA-C the strongest effects were for Asp114 with
resolution (P5 0.002) and Ser116 with chronicity
(P5 0.006) in the absence of an effect of tapasin, and
a weaker protective effect of Ser116 and tapasin G
(P5 0.011). Thus, consistent with our observations on
heterozygosity at the MHC, the effect of tapasin is
strongest in combination with HLA-B, rather than
HLA-A or HLA-C, alleles. This epistatic association is
unlikely to be due to linkage between tapasin and spe-
cific HLA-B alleles, as we found that no specific HLA-
B alleles with aspartate at position 114 were signifi-
cantly (P< 0.05) associated with the tapasin G allele
(Supporting Table 1).
The Association of Tapasin G With HCV Is Popu-
lation-Specific. To determine if the protective effect
of tapasin was universal, we tested a second cohort of
Caucasian individuals from the USA. Fifty-three indi-
viduals had resolved infection and 196 were chroni-
cally infected. Similar frequencies of tapasin alleles
were found in both groups. The tapasin G allele was
found in 43 (81.1%) resolvers versus 160 (81.7%)
chronically infected and the tapasin C allele was found
in 71.7% of resolvers and 74.0% of chronically
infected individuals (all P> 0.1) (Table 2b). Thus, the
effect of tapasin was confined to European Caucasians.
Comparison of the different HLA-class I alleles from
the two populations revealed slight but significant dif-
ferences between the HLA-A, HLA-B, and HLA-C al-
leles in both groups, which may be relevant to the lack
of association in this cohort (Supporting Table 2). To
confirm that this effect was indeed population-specific,
we typed a further UK cohort of 75 individuals at
high risk of HCV infection due to multiple episodes
of intravenous drug use but who remained seronega-
tive and aviremic. These individuals have detectable
T-cell responses, a protective KIR:HLA-C type, and
distinct serum cytokine profile, consistent with expo-
sure to HCV infection.26,31,32 As a comparator group
we typed a further 79 individuals from the UK with
chronic HCV infection. The tapasin G allele was pres-
ent in 63 (84%) individuals in the exposed seronega-
tive aviremic group, similar to that found in the UK
spontaneous resolvers, but this was not significantly
different from the 60 (76%) with the tapasin G allele
in the second UK chronically infected population (Ta-
ble 2c). However, there was an increased frequency of
HLA-B Asp114 in combination with tapasin G in the
Table 4. Logistic Regression Analysis of Tapasin G With
Specific Amino Acid Residues at the Three Different HLA
Class I Loci and the Outcome of Infection
a) HLA-A
P OR 95% CI
Tapasin G 0.001 2.29 1.42-3.70
Tapasin G1 Arg 156 P>0.1
Arg 156 P>0.1
b) HLA-B
P OR 95% CI
Tapasin G 0.001 2.72 1.75-5.04
Tapasin G1 Asp114 0.027 3.00 1.13-7.93
Tapasin G1 Asp156 0.048 2.79 1.01-7.68
Asp156 0.053 0.61 0.37-1.01
Asp114 0.079 0.65 0.40-1.05
Tapasin G1 Ser116 >0.1
Ser116 >0.1
c) HLA-C
P OR 95% CI
Tapasin G <0.001 2.33 1.45-3.74
Asp114 0.002 2.43 1.39-4.25
Ser116 0.006 0.51 0.31-0.82
Tapasin G1 Ser116 0.011 3.48 1.32-9.13
Tapasin G1 Asp114 0.058 0.34 0.11-1.04
An OR >1 indicates a positive association with resolution.
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exposed seronegative aviremic individuals as compared
to the chronically infected (54.8% versus 40.2%;
P< 0.04, OR5 1.8 95%, CI5 1.04-3.14) (Table 5).
Furthermore, they also had an increased frequency of
HLA-B Asp114 in combination with two tapasin G
alleles (16.4% versus 6.9%; P< 0.04, OR5 2.7, 95%,
CI5 1.05-6.70). Thus, tapasin G and HLA-B appear
to have a similar protective effect in this cohort.
Tapasin G Is Associated With Stronger IFN-c
CD81 T-Cell Responses in Chronic HCV Infec-
tion. To date the functional role of tapasin polymor-
phism on CD81 responses has not been described in
viral infection. Tapasin optimizes peptide:MHC class I
interactions, likely impacting priming and induction
of CD81 T cells. In order to determine whether there
is an effect of the tapasin polymorphism on antiviral
CD81 responses, we determined peptide-specific
CD81 responses from 42 patients with chronic HCV
genotype 1 infection who had HLA-B alleles with
aspartate at residue 114, as this was our most signifi-
cant association with the tapasin polymorphism in the
genetic studies. These alleles included B*18, B*35,
B*57, and B*58. PBMC were stimulated for 2 weeks,
using specific HLA-B restricted HCV-derived peptides
(Table 1), matched to the HLA-B allele of the patient
and analyzed for IFN-c secretion by flow cytometry.
In order to avoid confounding effects through HCV
genotype mismatches between patients and epitope
peptides, we restricted our analysis to patients infected
with HCV genotype 1, using only peptides identified
from this genotype. One hundred and ninety-one
assays using 16 different peptides were performed in
these individuals (145 assays in the 35 patients with
the tapasin G allele [median 4, range 1-8] versus 46
assays in the 10 patients without the tapasin G allele
[median 3, range 2-8]; P5 0.9). In patients with these
HLA-B alleles and also a tapasin G allele measurable
responses were made in 51 out of 145 (35.1%) assays
as compared to 8 out of 46 (17.3%) in patients with-
out a tapasin G allele (P5 0.02, OR5 2.58, 95%
CI5 1.05-6.5). Next, the magnitude of the response
to these peptides was compared. Individuals carrying a
tapasin G allele had a greater overall frequency of
CD81 T-cell responses compared to individuals with-
out the tapasin G allele (P5 0.037) (Fig. 3). Taken
together, our data suggest that the tapasin G allele and
specific HLA class I alleles may synergize to generate
stronger CD81 T-cell responses. As discussed below,
future studies performed in acute infection are
required to extend our observations from chronically
infected patients.
Discussion
The association of the tapasin G allele with out-
come in our cohort is consistent with the role of the
CD81 T-cell response in determining the outcome of
acute HCV infection. Furthermore, the functional data
in an unrelated cohort indicates that this polymor-
phism has a downstream effect on the magnitude of
the CD81 response. Thus, individuals with a protec-
tive tapasin allele have greater CD81 responses than
those without. The increased frequency of IFN-c-posi-
tive CD81 T cells following peptide stimulation in
these individuals may be related either to a larger pool
of memory CD8 T cells or alternatively memory T
cells that proliferate more efficiently. It is important to
note, however, that our functional CD81 T-cell data
Table 5. Association of Tapasin (Tsn) Alleles With
HLA-B Alleles With Asp 114 in the Exposed Seronegative
Aviremic and Second UK Chronic Populations
Exposed
Seronegative
(2n5 104)
Chronic
(2n5 102) P Value OR (95% CI)
HLA-B Asp1141 Tsn G 57 (54.8%) 41 (40.2%) 0.036 1.8 (1.04-3.14)
HLA-B Asp1141 Tsn C 50 (48.1%) 43 (42.1%) 0.4
HLA-B Asp1141 Tsn GG 17 (16.4%) 7 (6.9%) 0.034 2.65 (1.05-6.70)
Fig. 3. The tapasin G allele is associated with stronger IFN-c-pro-
ducing T-cell responses in individuals with an HLA-B allele with
Asp114. The results of intracellular cytokine staining for IFN-c on
CD81 T cells stimulated with various HCV-derived HLA restricted pep-
tides. All patients tested had an HLA-B allele with Asp114 and pep-
tides were matched to the HLA-B allele of the individual. Data are
plotted for individuals with and without a tapasin G allele.
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have several limitations. First, the strength of HCV-
specific CD81 T-cell memory responses may be con-
founded by viral sequence variations in the respective
CD81 T-cell epitopes. We thus analyzed the autolo-
gous viral sequences in a subset of patients. Impor-
tantly, viral sequence mutations occurred at very
similar frequencies in patients irrespective of tapasin
genotypes (CC: 9/18 epitopes, 50.0%; CG: 12/22,
54.6%; GG: 5/11, 45.45%; P> 0.1), indicating that
viral sequence variations did not substantial confound
our results. Second, the CD81 T-cell response in the
chronic phase of infection may not necessarily corre-
late with the CD81 T-cell response in the acute
phase of infection, when the outcome is determined.
Longitudinal analyses of patients with acute-persistent
infection as well as similar immunodominance of
CD81 T-cell responses in acute and chronic infection,
however, argue against this notion.8,29,33 Third, the
rather small number of patients per individual HLA al-
lele may influence our results. Thus, further studies in
the acute phase of infection are required to confirm our
finding that tapasin polymorphisms and specific HLA
class I alleles synergize to generate stronger antiviral
CD81 responses.
In the tapasin knockout mouse there is an alteration
in peptide presentation as compared to the wildtype
mouse.34 In these experiments the presence of tapasin
favors CD81 T-cell responses to peptides with slow
off-rates from MHC class I and its absence is associ-
ated with CD81 responses to peptides with a fast off-
rate. How this may be affected by a polymorphism in
tapasin is not clear. The R260T polymorphism is pres-
ent in one of the Ig-like domains of tapasin. In the
crystal structure it is in a loop, close to the site of
interaction with the oxido-reductase ERp57, which is
another key component of the peptide loading com-
plex involved in determining the peptide repertoire
expressed on the cell surface.35 Thus, the effect of this
polymorphism on the interaction with HLA class I is
not likely to be a direct effect on tapasin binding to
HLA class I. It may be a remote effect on HLA class I
binding, or alternatively an indirect effect mediated via
the interaction with ERp57.
The finding of an absence of tapasin association in
a second unrelated cohort is not unexpected, as these
are individuals who have a discrete ancestry and are
exposed to different viral populations.36,37 These dif-
ferences are especially noticeable at the MHC, which
is characterized by substantial population diversity. In
analyses of HLA class I different protective HLA class
I alleles are found in European as opposed to USA
cohorts.3-5 However, despite these population
differences, the levels of homozygosity at the MHC
were similar between the US and UK populations. For
instance, at HLA-B 9.2% of the US and 7.1% of the
UK populations were homozygous using four-digit
HLA typing.
Another source of confounding genetic effects
include resolution through different genetic pathways.
These include KIR and HLA-C, and also potentially
interleukin (IL)-28B. Subanalysis of the US cohort by
KIR ligand (HLA-C) type was not associated with any
significant findings (Supporting Table 3) and IL-28B is
thought to be protective in both US and UK Cauca-
sian populations.38 Thus, these known protective fac-
tors are unlikely to account for our observed
population differences. Additionally, there is diversity
in the prevalent HCV-infecting genotypes between the
USA and the UK,36,37 which may also impact the
mechanism of resolution of infection.
Our genetic data correlate well with the biochemis-
try of tapasin, with key residues being 114 and 156.16
Thus, for HLA-B*4402, which has Asp114 and
Asp156, the presence of a functional tapasin protein
alters the peptide repertoire.39 Thus, not only can
polymorphisms at these residues impact their interac-
tion with tapasin, but the specific residues that are
most significant in our study have been previously
identified by biochemical experiments. Overall, tapasin
is thought to be under purifying selection, being
well conserved across species with 84% amino acid
identity between human and sheep.40 This implies
that there is selection pressure to maintain the
sequence of tapasin and the coding SNP is likely to
be the most relevant due to its potential for func-
tional interaction with HLA or ERp57. Tapasin is
thus likely to be important in generating optimal
HLA class I peptide repertoires in the antiviral
immune response. Consideration of this polymor-
phism may be important for the implementation of
peptide vaccination strategies for HCV.
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